AI Drives Breakthroughs in Pharma R&D, But Challenges Remain in Regulation, Data, and Patient Trust
-
AI is delivering breakthroughs in pharma R&D, enabling prediction of patient responses, increasing clinical trial success rates, and determining individualized treatments.
-
Sanofi is seeing major impacts from AI, with over 80% prediction accuracy in models and majority of projects enabled by AI and ML.
-
There are challenges ahead, including AI regulation differences, data quality concerns, pricing restrictions stifling R&D investment, reduced access to capital for biotech startups, and building patient trust.
-
Decentralized clinical trials and inclusive trial designs can help build patient trust and acceptance of novel therapies.
-
Increased collaboration among stakeholders is needed to drive faster discoveries and overcome roadblocks in utilizing AI.